{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:47:08Z","timestamp":1759837628934,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute of Health Research","doi-asserted-by":"crossref","award":["Biomedical Research Centre at King's College London and South London and Maudsley NHS Foundation Trust"],"award-info":[{"award-number":["Biomedical Research Centre at King's College London and South London and Maudsley NHS Foundation Trust"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>People with dementia may have indications for aspirin prescription and clinicians are asked to balance the potential risks against benefits. This review examines the evidence for the risk and benefit of long-term aspirin use in people with dementia aged over 65\u00a0years, including randomised controlled trials and observational studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched three databases for research published between 2007 and 2020. Each eligible article was assessed for risk of bias, and confidence in findings was rated using Grading of Recommendations Assessment, Development and Evaluation (GRADE).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four papers met inclusion criteria: one randomised controlled trial, two cohort studies, and one with pooled data. All looked only at dementia of Alzheimer\u2019s type, and none addressed myocardial or cerebral infarction as outcomes. Dementia progression was reported by two studies, with conflicting results. The trial found no significant effect of aspirin on mortality (odds ratio aspirin vs. no aspirin 1.07, 95% confidence interval 0.58\u20131.97) but found more events of severe bleeding with aspirin (OR aspirin vs. no aspirin 6.9, 1.5\u201331.2). An excess in intracranial haemorrhage in the aspirin group was judged plausible based on two non-randomised studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The review findings are limited because studies include only people with Alzheimer\u2019s-type dementia and lack confirmatory studies, although an increased risk of bleeding events is recognised. Further research that addresses the benefits and risks of aspirin in more representative groups of people with dementia is needed to guide prescribing decisions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-021-03089-x","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T20:03:27Z","timestamp":1611345807000},"page":"943-954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Aspirin in people with dementia, long-term benefits, and harms: a systematic review"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-4646","authenticated-orcid":false,"given":"Katrina A. S.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-2054","authenticated-orcid":false,"given":"Delia","family":"Bishara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1989-7327","authenticated-orcid":false,"given":"Mariam","family":"Molokhia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-1686","authenticated-orcid":false,"given":"Christoph","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-303X","authenticated-orcid":false,"given":"Gayan","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4435-6397","authenticated-orcid":false,"given":"Robert J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"3089_CR1","unstructured":"Alzheimer\u2019s Disease International, World Health Organization (2012) Dementia: a public health priority. Department of Mental Health and Substance Abuse. http:\/\/www.who.int\/mental_health\/publications\/dementia_report_2012. Accessed 21 July 2020"},{"issue":"12","key":"3089_CR2","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/gps.4163","volume":"29","author":"D Bishara","year":"2014","unstructured":"Bishara D, Harwood D (2014) Safe prescribing of physical health medication in patients with dementia. Int J Geriatr Psychiatry 29(12):1230\u20131241. https:\/\/doi.org\/10.1002\/gps.4163","journal-title":"Int J Geriatr Psychiatry"},{"issue":"8","key":"3089_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/14740338.2018.1497156","volume":"17","author":"TC Eshetie","year":"2018","unstructured":"Eshetie TC, Nguyen TA, Gillam MH, Kalisch Ellett LM (2018) A narrative review of problems with medicines use in people with dementia. Expert Opin Drug Saf 17(8):825\u2013836. https:\/\/doi.org\/10.1080\/14740338.2018.1497156","journal-title":"Expert Opin Drug Saf"},{"key":"3089_CR4","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P (2017) Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 357:j2099. https:\/\/doi.org\/10.1136\/bmj.j2099","journal-title":"BMJ."},{"issue":"6921","key":"3089_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","unstructured":"Antiplatelet Trialists\u2019 Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019 Collaboration. BMJ (Clin Res Ed) 308(6921):81\u2013106","journal-title":"BMJ (Clin Res Ed)"},{"key":"3089_CR6","doi-asserted-by":"publisher","first-page":"172762","DOI":"10.1016\/j.ejphar.2019.172762","volume":"866","author":"J Hybiak","year":"2020","unstructured":"Hybiak J, Broniarek I, Kiryczynski G, Los LD, Rosik J, Machaj F et al (2020) Aspirin and its pleiotropic application. Eur J Pharmacol 866:172762. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172762","journal-title":"Eur J Pharmacol"},{"issue":"9678","key":"3089_CR7","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Antithrombotic Trialists Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 373(9678):1849\u20131860. https:\/\/doi.org\/10.1016\/S0140-6736(09)60503-1","journal-title":"Lancet."},{"issue":"7","key":"3089_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.4321\/S1130-01082011000700005","volume":"103","author":"PW Jorgensen","year":"2011","unstructured":"Jorgensen PW, Calleja EL, Gaso PS, Matarranz del Amo M, Navarro RA, Sanchez JM (2011) Antiagregation and anticoagulation, relationship with upper gastrointestinal bleeding. Rev Esp Enferm Dig 103(7):360\u2013365","journal-title":"Rev Esp Enferm Dig"},{"issue":"8","key":"3089_CR9","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1161\/01.STR.0000174189.81153.85","volume":"36","author":"PB Gorelick","year":"2005","unstructured":"Gorelick PB, Weisman SM (2005) Risk of hemorrhagic stroke with aspirin use: an update. Stroke 36(8):1801\u20131807. https:\/\/doi.org\/10.1161\/01.STR.0000174189.81153.85","journal-title":"Stroke"},{"issue":"3","key":"3089_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40256-018-0313-0","volume":"19","author":"M Sugawara","year":"2019","unstructured":"Sugawara M, Goto Y, Yamazaki T, Teramoto T, Oikawa S, Shimada K et al (2019) Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: subanalysis of a randomized clinical trial (JPPP-70). Am J Cardiovasc Drugs 19(3):299\u2013311. https:\/\/doi.org\/10.1007\/s40256-018-0313-0","journal-title":"Am J Cardiovasc Drugs"},{"issue":"16","key":"3089_CR11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM, ASPREE Investigator Group (2018) Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 379(16):1509\u20131518. https:\/\/doi.org\/10.1056\/NEJMoa1805819","journal-title":"N Engl J Med"},{"issue":"6","key":"3089_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.2174\/156720512801322555","volume":"9","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Sonnen JA, Montine KS, Crane PK, Larson EB (2012) Adult Changes in Thought study: dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics. Curr Alzheimer Res 9(6):718\u2013723. https:\/\/doi.org\/10.2174\/156720512801322555","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"3089_CR13","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1212\/wnl.0000000000009277","volume":"95","author":"J Ryan","year":"2020","unstructured":"Ryan J, Storey E, Murray AM, Woods RL, Wolfe R, Reid CM, Nelson MR, Chong TTJ, Williamson JD, Ward SA, Lockery JE, Orchard SG, Trevaks R, Kirpach B, Newman AB, Ernst ME, McNeil JJ, Shah RC, on behalf of the ASPREE Investigator Group (2020) Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. 95(3):e320\u2013ee31. https:\/\/doi.org\/10.1212\/wnl.0000000000009277","journal-title":"Neurology."},{"issue":"8","key":"3089_CR14","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/jgs.14883","volume":"65","author":"N Veronese","year":"2017","unstructured":"Veronese N, Stubbs B, Maggi S, Thompson T, Schofield P, Muller C, Tseng PT, Lin PY, Carvalho AF, Solmi M (2017) Low-dose aspirin use and cognitive function in older age: a systematic review and meta-analysis. J Am Geriatr Soc 65(8):1763\u20131768. https:\/\/doi.org\/10.1111\/jgs.14883","journal-title":"J Am Geriatr Soc"},{"key":"3089_CR15","doi-asserted-by":"publisher","unstructured":"Jaturapatporn D, Isaac MGEKN, McCleery J, Tabet N (2012) Aspirin, steroidal and non\u2010steroidal anti\u2010inflammatory drugs for the treatment of Alzheimer's disease SO. Cochrane Database Syst Rev 1465\u20131858.\u00a0https:\/\/doi.org\/10.1002\/14651858.CD006378.pub2","DOI":"10.1002\/14651858.CD006378.pub2"},{"key":"3089_CR16","doi-asserted-by":"publisher","unstructured":"Rands G, Orrel M, Spector A, Williams P (2004) Aspirin for vascular dementia SO. Cochrane Database Syst Rev 1465\u20131858. https:\/\/doi.org\/10.1002\/14651858.CD001296","DOI":"10.1002\/14651858.CD001296"},{"issue":"8","key":"3089_CR17","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1161\/strokeaha.120.029454","volume":"51","author":"C McHutchison","year":"2020","unstructured":"McHutchison C, Blair GW, Appleton JP, Chappell FM, Doubal F, Bath PM, Wardlaw JM (2020) Cilostazol for secondary prevention of stroke and cognitive decline systematic review and meta-analysis. Stroke. 51(8):2374\u20132385. https:\/\/doi.org\/10.1161\/strokeaha.120.029454","journal-title":"Stroke."},{"key":"3089_CR18","doi-asserted-by":"publisher","unstructured":"Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Smith CT et al (2020) Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database Syst Rev 4. https:\/\/doi.org\/10.1002\/14651858.CD011459.pub2","DOI":"10.1002\/14651858.CD011459.pub2"},{"key":"3089_CR19","doi-asserted-by":"publisher","unstructured":"Davis KA, Farooq S, Hayes JF, John A, Lee W, MacCabe JH et al (2019) Pharmacoepidemiology research: delivering evidence about drug safety and effectiveness in mental health. Lancet Psychiatry. https:\/\/doi.org\/10.1016\/S2215-0366(19)30298-6","DOI":"10.1016\/S2215-0366(19)30298-6"},{"issue":"7","key":"3089_CR20","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"3089_CR21","doi-asserted-by":"publisher","first-page":"i157","DOI":"10.1136\/bmj.i157","volume":"352","author":"L Zorzela","year":"2016","unstructured":"Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S, PRISMA harms group (2016) PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 352:i157. https:\/\/doi.org\/10.1136\/bmj.i157","journal-title":"BMJ."},{"key":"3089_CR22","doi-asserted-by":"crossref","unstructured":"Davis KAS, Bishara D, Molokhia M, Perera G, Stewart R (2019) Aspirin in people with dementia, long-term benefits and harms: protocol for a systematic review. In: International prospective register of systematic reviews. National Institute for Health Research. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42019144773. Accessed 21 July 2020","DOI":"10.1007\/s00228-021-03089-x"},{"key":"3089_CR23","doi-asserted-by":"publisher","first-page":"14898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"J Sterne","year":"2019","unstructured":"Sterne J, Savovi\u0107 J, Page M, Elbers R, Blencowe N, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:14898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3089_CR24","volume-title":"Clinical Epidemiology","author":"G Wells","year":"2019","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al (2019) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: Clinical Epidemiology. The Ottawa Hospital, Ontario, Canada http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 21 July 2020"},{"key":"3089_CR25","unstructured":"The Nordic Cochrane Centre (2014) Review Manager (RevMan) [Computer program]. In: The Cochrane Collaboration, editor. Copenhagen"},{"key":"3089_CR26","unstructured":"Evidence Prime Inc (2015) GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. In: McMaster University, editor. Available from gradepro.org"},{"key":"3089_CR27","unstructured":"Higgins J, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The cochrane collaboration. Available from https:\/\/handbook.cochrane.org. Archived version https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/. Accessed 21 Jan 2021"},{"issue":"1","key":"3089_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1474-4422(07)70293-4","volume":"7","author":"A. D. Collaborative Group","year":"2008","unstructured":"A. D. Collaborative Group (2008) Aspirin in Alzheimer\u2019s disease (AD2000): a randomised open-label trial. Lancet Neurol 7(1):41\u201349. https:\/\/doi.org\/10.1016\/S1474-4422(07)70293-4","journal-title":"Lancet Neurol"},{"issue":"2","key":"3089_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3233\/jad-170665","volume":"61","author":"C Ferrari","year":"2018","unstructured":"Ferrari C, Lombardi G, Polito C, Lucidi G, Bagnoli S, Piaceri I, Nacmias B, Berti V, Rizzuto D, Fratiglioni L, Sorbi S (2018) Alzheimer\u2019s disease progression: factors influencing cognitive decline. J Alzheimers Dis 61(2):785\u2013791. https:\/\/doi.org\/10.3233\/jad-170665","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"3089_CR30","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1161\/strokeaha.109.576975","volume":"41","author":"H Thoonsen","year":"2010","unstructured":"Thoonsen H, Richard E, Bentham P, Gray R, van Geloven N, De Haan RJ et al (2010) Aspirin in Alzheimer\u2019s disease: increased risk of intracerebral hemorrhage: cause for concern? Stroke. 41(11):2690\u20132692. https:\/\/doi.org\/10.1161\/strokeaha.109.576975","journal-title":"Stroke."},{"issue":"1","key":"3089_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3233\/jad-190762","volume":"73","author":"TL Lee","year":"2020","unstructured":"Lee TL, Liu CH, Chang YM, Lin TY, Chien CY, Chen CH, Tsai KJ, Lin SH, Sung PS (2020) The impact of antiplatelet use on the risk of intracerebral hemorrhage in patients with Alzheimer\u2019s disease: a nationwide cohort study. J Alzheimers Dis 73(1):297\u2013306. https:\/\/doi.org\/10.3233\/jad-190762","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"3089_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1532-5415.2009.02217.x","volume":"57","author":"E Richard","year":"2009","unstructured":"Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA (2009) Vascular care in patients with Alzheimer\u2019s disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc 57(5):797\u2013805. https:\/\/doi.org\/10.1111\/j.1532-5415.2009.02217.x","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"3089_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1532-5415.1989.tb05688.x","volume":"37","author":"JS Meyer","year":"1989","unstructured":"Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J (1989) Randomized clinical trial of daily aspirin therapy in multi-infarct dementia: a pilot study. J Am Geriatr Soc 37(6):549\u2013555","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"3089_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/gps.857","volume":"18","author":"M Devine","year":"2003","unstructured":"Devine M, Rands G (2003) Does aspirin affect outcome in vascular dementia? A retrospective case-notes analysis. Int J Geriatr Psychiatry 18(5):425\u2013431","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"3089_CR35","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s00535-015-1038-3","volume":"50","author":"A Lanas","year":"2015","unstructured":"Lanas A, Gargallo CJ (2015) Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol 50(6):626\u2013637","journal-title":"J Gastroenterol"},{"issue":"3","key":"3089_CR36","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","volume":"157","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O et al (2019) Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 157(3):682. https:\/\/doi.org\/10.1053\/j.gastro.2019.05.056","journal-title":"Gastroenterology"},{"issue":"4","key":"3089_CR37","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"By the American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","unstructured":"By the American Geriatrics Society Beers Criteria\u00ae Update Expert Panel (2019) American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc 67(4):674\u2013694. https:\/\/doi.org\/10.1111\/jgs.15767","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"3089_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1192\/bjb.2019.43","volume":"44","author":"D Bishara","year":"2020","unstructured":"Bishara D, Scott C, Stewart R, Taylor D, Harwood D, Codling D, Banwell C, Sauer J (2020) Safe prescribing in cognitively vulnerable patients: the use of the anticholinergic effect on cognition (AEC) tool in older adult mental health services. BJPsych Bulletin 44(1):26\u201330. https:\/\/doi.org\/10.1192\/bjb.2019.43","journal-title":"BJPsych Bulletin"},{"issue":"12","key":"3089_CR39","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40266-017-0505-3","volume":"34","author":"M McGrattan","year":"2017","unstructured":"McGrattan M, Ryan C, Barry HE, Hughes CM (2017) Interventions to improve medicines management for people with dementia: a systematic review. Drugs Aging 34(12):907\u2013916. https:\/\/doi.org\/10.1007\/s40266-017-0505-3","journal-title":"Drugs Aging"},{"issue":"3","key":"3089_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2174\/157488471003150820150330","volume":"10","author":"E Reeve","year":"2015","unstructured":"Reeve E, Simon Bell J, Hilmer SN (2015) Barriers to optimising prescribing and deprescribing in older adults with dementia: a narrative review. Curr Clin Pharmacol 10(3):168\u2013177","journal-title":"Curr Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03089-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:15:17Z","timestamp":1623068117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03089-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3089"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03089-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"28 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RS declares research funding\/support from Janssen, GSK, and Takeda in the last 3\u00a0years. All other authors declare that they have no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participation"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}